This post was originally published on this site
(Reuters) – Australia’s medical regulator said on Tuesday it had granted provisional determination to AstraZeneca (NASDAQ:AZN) for its antibody cocktail, the first protective shot other than vaccines against the COVID-19.
The Therapeutic Goods Administration added that the Anglo-Swedish drugmaker is now eligible to apply for provisional registration for the antibody cocktail, EVUSHELD, in Australia.
